Alexion Pharmaceuticals (NASDAQ:ALXN) had its target price lifted by Morgan Stanley from $148.00 to $151.00 in a report issued on Friday. They currently have an overweight rating on the biopharmaceutical company’s stock.

ALXN has been the subject of several other reports. TheStreet cut Alexion Pharmaceuticals from a b- rating to a c+ rating in a research report on Friday, November 10th. BidaskClub upgraded Alexion Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, December 27th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a hold rating to a buy rating and set a $144.00 price target for the company in a research report on Tuesday, October 31st. Credit Suisse Group reiterated a buy rating and set a $166.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. Finally, Raymond James Financial reiterated an outperform rating and set a $130.00 price target (down from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $152.77.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at $115.43 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10. Alexion Pharmaceuticals has a 12-month low of $96.18 and a 12-month high of $149.34. The company has a market capitalization of $25,790.00, a P/E ratio of 58.59, a P/E/G ratio of 0.95 and a beta of 1.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The firm had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same period in the previous year, the business earned $1.26 earnings per share. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. analysts predict that Alexion Pharmaceuticals will post 6.25 EPS for the current fiscal year.

In other news, CEO Ludwig Hantson sold 13,245 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $1,540,525.95. Following the completion of the transaction, the chief executive officer now directly owns 131,425 shares in the company, valued at approximately $15,286,041.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Paul J. Clancy sold 6,079 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $707,048.49. Following the transaction, the chief financial officer now owns 95,093 shares of the company’s stock, valued at $11,060,266.83. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,930 shares of company stock valued at $3,378,199. Company insiders own 4.35% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC purchased a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth $147,000. Dupont Capital Management Corp purchased a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth $156,000. BT Investment Management Ltd purchased a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth $165,000. Beacon Investment Advisory Services Inc. purchased a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth $201,000. Finally, Invictus RG purchased a new position in shares of Alexion Pharmaceuticals during the 3rd quarter worth $202,000. Institutional investors and hedge funds own 94.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://theolympiareport.com/2018/02/13/morgan-stanley-boosts-alexion-pharmaceuticals-alxn-price-target-to-151-00.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.